Cited 0 times in

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study

Authors
 Edward B Garon  ;  Byoung Chul Cho  ;  Alexander Luft  ;  Jorge Alatorre-Alexander  ;  Sarayut Lucien Geater  ;  Dmytro Trukhin  ;  Sang-We Kim  ;  Grygorii Ursol  ;  Maen Hussein  ;  Farah Louise Lim  ;  Cheng-Ta Yang  ;  Luiz Henrique Araujo  ;  Haruhiro Saito  ;  Niels Reinmuth  ;  Milena Kohlmann  ;  Caitlin Lowery  ;  Helen Mann  ;  Solange Peters  ;  Tony S Mok  ;  Melissa L Johnson 
Citation
 CLINICAL LUNG CANCER, Vol.25(3) : 266-273.e5, 2024-05 
Journal Title
CLINICAL LUNG CANCER
ISSN
 1525-7304 
Issue Date
2024-05
MeSH
Antibodies, Monoclonal* / administration & dosage ; Antibodies, Monoclonal* / therapeutic use ; Antibodies, Monoclonal, Humanized* / administration & dosage ; Antibodies, Monoclonal, Humanized* / therapeutic use ; Antineoplastic Combined Chemotherapy Protocols* / therapeutic use ; B7-H1 Antigen* / antagonists & inhibitors ; B7-H1 Antigen* / metabolism ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / pathology ; Female ; Humans ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / pathology ; Male ; Treatment Outcome
Keywords
Clinical trial ; Cytotoxic T-lymphocyte-associated antigen 4 ; Immune checkpoint inhibitor ; Immunotherapy ; Programmed cell death ligand-1
Files in This Item:
T202405545.pdf Download
DOI
38584069
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/200583
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links